Merck: new findings on Keytruda immunotherapy.
(CercleFinance.com) - Last weekend at the ASCO meeting in Chicago Merck has unveiled an entire series of encouraging results about its immunotherapy drug Keytruda.
In particular the US drugmaker said that the molecule, in combination with Incyte's Epacadostat, demonstrated activity in clinical trial of patients with advanced non-small cell lung cancer (NSCLC).
With monitoring of over one year, Keytruda also showed continued overall survival benefit over chemotherapy as second-line treatment for advanced urothelial carcinoma patients post-platinum failure.
With almost three years' monitoring, the drug demonstrated improved survival benefit compared to Bristol-Myers Squibb's Ipilimumab in advanced melanoma.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
In particular the US drugmaker said that the molecule, in combination with Incyte's Epacadostat, demonstrated activity in clinical trial of patients with advanced non-small cell lung cancer (NSCLC).
With monitoring of over one year, Keytruda also showed continued overall survival benefit over chemotherapy as second-line treatment for advanced urothelial carcinoma patients post-platinum failure.
With almost three years' monitoring, the drug demonstrated improved survival benefit compared to Bristol-Myers Squibb's Ipilimumab in advanced melanoma.
Copyright (c) 2017 CercleFinance.com. All rights reserved.